Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

belimumab

- PMLiVE

smartbax licenses compound from Aicuris for next-generation antibiotic development

The new programme addresses the urgent unmet medical need for new therapies to tackle antibiotic-resistant infections

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

Lilly and MeiraGTx partner in $475m ophthalmology deal

The companies will develop and commercialise therapies for genetic conditions

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

BMS acquires Orbital Therapeutics in $1.5bn deal

The deal includes several next-gen cell therapy candidates for autoimmune diseases

- PMLiVE

Eli Lilly’s Inluriyo approved by FDA for breast cancer

The oral drug can be used to treat advanced or metastatic breast cancer

- PMLiVE

Innovation in Action at AAFP FMX 2025

This year, Medscape Education is redefining the live learning experience at AAFP FMX 2025. With 8 groundbreaking, accredited symposia, we are proud to be at the heart of the meeting,...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links